Ten post jest także dostępny w języku: polski
BioNTech has announced the establishment of a regional headquarters in Southeast Asia in Singapore. A fully integrated mRNA production facility is also to be established there with the support of the Singapore Economic Development Board.
Vaccine production accelerates
BioNTech plans to open an office in Singapore and begin construction of a manufacturing facility in 2021, subject to plan approval. Operations are scheduled to begin in 2023. The company said the new facility will employ 80 people.
The new mRNA manufacturing facility will be adapted to produce a range of novel mRNA vaccines and drugs for infectious diseases, as well as cancer drugs. It will be BioNTech’s first production facility outside Europe. Its production capacity is estimated at several hundred million doses of mRNA-based vaccines, depending on the type of vaccine.
Following the establishment of the US headquarters in Cambridge, Massachusetts in 2020, the establishment of BioNTech’s headquarters in Southeast Asia marks a milestone in the company’s international expansion, it stated.
Vaccination for COVID-19 under the age of 18
Furthermore, earlier this week, Pfizer and BioNTech announced that the US Food and Drug Administration (FDA) has received emergency use approval (EUA) for their COVID-19 vaccine. Under this provision, the vaccine can be used in people aged 12 to 15 years. This is the first COVID-19 vaccine approved in the US for use in this age group.
It is worth noting that the Pfizer/BioNTech formulation for COVID-19 in the Phase III study was 100% effective and generally well tolerated in participants aged 12 to 15 years. Data have also been submitted to the European Medicines Agency (EMA) and other global regulatory authorities, with additional authorizations expected in the coming weeks.